Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

Boehringer Ingelheim. (8/2/18). "Press Release: Boehringer Ingelheim Launches the Initiative In Reach Africa to Address Key Healthcare Infrastructure and Access Priorities across Africa". Ingelheim.

Organisation Organisation Boehringer Ingelheim (Group)
Products Product healthcare
  Product 2 pharmaceutical
     


> ‘In Reach Africa’ to facilitate quality and innovative human and animal healthcare access across the continent

> Series of activities and workshops already started

> Initiative underlines the company’s desire to provide more health and improve lives of patients on the continent


Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced recently the launch of the ‘In Reach Africa’ program, an initiative aimed at facilitating quality and innovative human and animal healthcare access across the African continent.

The program is set to kick off in Kenya and to expand throughout major African markets including Nigeria, Ghana, Ethiopia, Uganda, Mozambique, Tanzania, Zambia, Zimbabwe and Rwanda. It comprises a range of key elements that aim at adding more value to overall health systems, in an effort to drive access to care, support with the development of innovative health solutions, creating community based partnerships and raising awareness around key disease areas as well as prevention mechanisms.

A series of activities and workshops that are the building blocks of the newly launched program already started in July as for example the ‘Making More Health (MMH) Accelerator program. This program supports social health entrepreneurs to strengthen and scale their work, by bringing some of the best experiences in social and health innovation as well as global health to improve access across Sub-Saharan Africa. Empowering individuals is a core part of the initiative’s strategy and the fundamental element throughout ‘In Reach Africa’.

MMH is a long-term global initiative driven by Boehringer Ingelheim in partnership with Ashoka, a global non-governmental organization. Through MMH in Kenya, Boehringer Ingelheim and Askoka supported iSikCure, an application developed to improve access to quality care and safe medicine. In 2017, Boehringer Ingelheim, in partnership with Access Afya and PharmAccess, launched Akiba Ya Roho, a micro-savings program geared towards driving more healthcare awareness and overall understanding and management of non-communicable disease in some rural areas within Kenya.

"‘In Reach Africa’ shares a vision of driving accessibility, sustainability and innovation through enhancing health systems in Africa by providing an accessible range of medication and healthcare solutions, increasing awareness of key disease priorities through reach and enriching knowledge and education initiatives. In doing so, it is designed to add more value to the socioeconomic structure by working with and supporting low income families on multiple fronts,” said Yew Looi Liew, Head of Corporate Division Prescription Medicine Emerging Markets at Boehringer Ingelheim.

Reducing the avoidable burden caused by Non Communicable Diseases (NCDs) is central to the initiative. (NCDs) are a silent epidemic in low and middle-income countries, which account for 75 per cent of global NCDs deaths. Africa is expected to experience 3.9 million NCD-related deaths a year by 2020, a rise of more than 20 per cent.1 “Accordingly, we need to commit ourselves as an organization to working together with all other healthcare players to build an infrastructure that is sustainable, and one, which can ensure needed therapies are available in even the most remote areas. At Boehringer Ingelheim, we believe that everyone should have access to good health, no matter where they live,” commented Enrique Manzoni, Regional Managing Director – Middle East, Turkey, Africa (META) at Boehringer Ingelheim.


1 Africa’s health crisis needs a focus on systems, not people | https://www.ft.com/content/8f909e26-bd65-11e7-9836-b25f8adaa111


Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.


Making More Health

Making More Health (MMH) is a global initiative by the pharmaceutical company Boehringer Ingelheim in cooperation with Ashoka, a non-governmental organisation. Aiming to improve health for humans, animals and communities worldwide Making More Health pursues a multitude of approaches to finding solutions and tailoring these solutions to specific projects.

“By supporting and connecting social entrepreneurs in the healthcare industry, Boehringer Ingelheim seeks to have an impact on improving health beyond its core business. We do not want to limit ourselves to linear approaches to solutions. Indeed, since the initiative’s inception, we have focused on a multitude of issues and activities while supporting lateral thinking and networking. Making More Health also plays a very significant role within the company. We want to show our employees how important it is to be dedicated to social issues because it fosters new ways of thinking beyond traditional approaches,” explains Manuela Pastore, manager of Making More Health at Boehringer Ingelheim.

Boehringer Ingelheim employees can become involved in Making More Health in a variety of ways. With the MMH Executive in Residence Program, Boehringer Ingelheim employees go on location to support the projects of social entrepreneurs. The MMH Youth Venture Program supports the next generation in developing solutions for the healthcare industry, thereby encouraging social entrepreneurship and action.


Media contact

Maria Isabel Rodriguez Fernandez
Media + PR
Phone +49 6132 77 143007
Mobile +49 151 150 26111
Fax +49 6132 77 6601
› E-mail

Binger Straße 173
55216 Ingelheim am Rhein
GERMANY

   
Record changed: 2018-08-11

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Boehringer Ingelheim (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top